Our technological innovation platform called “CleanWeb-MAP” (CleanWeb Managed Access Programme) facilitates access to new drugs by eligible patients.
There are multiple terms that fall under the umbrella of MAP, including Compassionate Use, Early Access, Named Patient Use and Individual Patient Request Programmes to name but a few. The terms used may vary from country to country depending on local laws and regulations. Our module is closely linked to our CleanWeb software platform for medical data collection, it enables self-registration of prescribing physicians and pharmacists, for each new product related to MAP.
• MAPs provide alternative treatments to patients with life-threatening diseases with no therapeutic options
• CleanWeb-MAP meets local laws and regulations Seamless Managed Access Programmes
Entrust your project
to our expert
data management team
Allows you to gain valuable early experience with a product
CleanWeb-MAP facilitates the management of MAPs in real-life conditions
Each role and access are clearly defined Physicians, Nurses, Medical Advisor, Programme Manager, Pharmacovigilance officer, Logistics perfectly interact in the MAP cycle process.
The ordering process and the availability of drugs are assured in interaction with any external system and data source.
CleanWeb-MAP allows for the involvement of other stakeholders and for the integration of many additional behaviours (e.g., Pharmacist).
Do you want to learn more about our e-health solution? Just fill in the form and we will get back to you shortly
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
February 29, 2024
4 and 5 march 2024 TELEMEDICINE TECHNOLOGIES is delighted to announce its participation in the upcoming ACDM24 conference, the largest European event in clinical data management for 2024! Join us in Copenhagen from March 3rd to 5th, where industry leaders and experts will gather to explore the latest trends in the field. Christophe Golenvaux and […]
February 29, 2024
Bio Pharm International FDA’s Drug Safety Priorities FY23 describes the center’s key safety programs and activities involved in promoting and protecting public health. On Feb. 15, 2024, FDA’s Center for Drug Evaluation and Research (CDER) released its report, Drug Safety Priorities FY23. The report describes the center’s key safety programs and activities involved in promoting and […]
February 29, 2024
Fierce Biotech In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, multidisciplinary, and cost-effective approaches. Pathways have become a critical strategy for both physicians and payers to streamline treatment decision-making, standardize evidence-based care, improve patient outcomes […]